Interdisziplinäre Strategien zur Prävention und Therapie der MASLD

Die metabolische dysfunktionsassoziierte steatotische Lebererkrankung (MASLD) gehört zu den häufigsten Ursachen der Leberzirrhose und des hepatozellulären Karzinoms. Die Ausprägung des metabolischen Syndroms und insbesondere der Diabetes mellitus Typ 2 sind hierbei wesentliche Risikofaktoren für die Progression der Lebererkrankung, aber auch für die gehäuft auftretenden kardiovaskulären Komplikationen. Die Patienten profitieren daher in besonderem Maße von einer interdisziplinären Behandlung. Dieser Artikel gibt eine Übersicht über empfohlene Strategien zur Prävention und Therapie der MASLD.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common causes of liver cirrhosis and hepatocellular carcinoma. The severity of the metabolic syndrome and in particular type 2 diabetes are major risk factors for the progression of liver disease, but also for the frequent occurrence of cardiovascular complications. Patients therefore benefit in particular from an interdisciplinary treatment. This article provides an overview of recommended strategies for the prevention and treatment of MASLD.

Schlüsselwörter

MASH - metabolisches Syndrom - Leberzirrhose

Keywords

MASH - metabolic syndrome - liver cirrhosis

• Literatur

• 1 Younossi ZM, Golabi P, Paik JM. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335-1347
• 2 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; 81: 492-542
• 3 Younossi ZM, Paik JM, Stepanova M. et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol 2024; 80: 694-701
• 4 Sironi AM, Sicari R, Folli F. et al. Ectopic fat storage, insulin resistance, and hypertension. Curr Pharm Des 2011; 17: 3074-3080
• 5 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1–9
• 6 Hagström H, Shang Y, Hegmar H. et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol 2024; 9: 944-956
• 7 Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol 2020; 72: 1196-209
• 8 Tamaki N, Ahlholm N, Luukkonen PK. et al. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest 2022; 132
• 9 Bassegoda O, Rivera-Esteban J, Serra I. et al. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. Hepatol Commun 2022; 6: 3212-3222
• 10 Pons M, Augustin S, Scheiner B. et al. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. Am J Gastroenterol 2021; 116: 723-732
• 11 Harrison SA, Bedossa P, Guy CD. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024; 390: 497-509
• 12 Goyal A, Arora H, Arora S. Prevalence of fatty liver in metabolic syndrome. J Family Med Prim Care 2020; 9: 3246-3250
• 13 Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67: 829-846
• 14 Lassailly G, Caiazzo R, Ntandja-Wandji L-C. et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterol 2020; 159: 1290-1301.e5
• 15 Abu Dayyeh BK, Edmundowicz S, Thompson CC. Clinical Practice Update: Expert Review on Endoscopic Bariatric Therapies. Gastroenterol 2017; 152: 716-729
• 16 Wong HJ, Sim B, Teo YH. et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025; 48: 292-300
• 17 Mao X, Zhang X, Kam L. et al. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut 2024; 73: 2054-2061
• 18 Lin J, Huang Y, Xu B. et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 2025; 389: e083735
• 19 Sanyal AJ, Newsome PN, Kliers I. et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. N Engl J Med 2025; 392: 2089-2099
• 20 Loomba R, Hartman ML, Lawitz EJ. et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024; 391: 299-310